Dominari (NASDAQ:DOMH) Lowered to “Hold” Rating by Wall Street Zen

Wall Street Zen cut shares of Dominari (NASDAQ:DOMH) from a buy rating to a hold rating in a research note released on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Dominari in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Dominari has a consensus rating of “Sell”.

Dominari Stock Performance

NASDAQ DOMH opened at $4.98 on Friday. The company has a market capitalization of $79.74 million, a PE ratio of -2.10 and a beta of 0.66. Dominari has a 52-week low of $0.83 and a 52-week high of $13.58. The company has a 50-day simple moving average of $6.04 and a 200 day simple moving average of $5.63.

Dominari Dividend Announcement

The business also recently announced a special dividend, which was paid on Friday, September 26th. Shareholders of record on Wednesday, September 3rd were paid a $0.22 dividend. The ex-dividend date was Wednesday, September 3rd.

Institutional Investors Weigh In On Dominari

A number of institutional investors and hedge funds have recently modified their holdings of DOMH. Magnus Financial Group LLC bought a new position in shares of Dominari in the second quarter valued at approximately $136,000. Vanguard Group Inc. lifted its stake in Dominari by 8.0% in the 3rd quarter. Vanguard Group Inc. now owns 345,896 shares of the company’s stock worth $2,452,000 after purchasing an additional 25,694 shares in the last quarter. Two Sigma Investments LP bought a new position in Dominari in the 3rd quarter valued at $771,000. Geode Capital Management LLC grew its position in shares of Dominari by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 66,283 shares of the company’s stock valued at $361,000 after purchasing an additional 1,866 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Dominari in the second quarter worth $158,000. 42.48% of the stock is owned by hedge funds and other institutional investors.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.